Aptose Biosciences Files 8-K

Ticker: APTOF · Form: 8-K · Filed: May 14, 2025 · CIK: 882361

Sentiment: neutral

Topics: financial-statements, regulation-fd, corporate-history

Related Tickers: APTO

TL;DR

APTO filed an 8-K on 5/14/25 - check for Reg FD and financials.

AI Summary

Aptose Biosciences Inc. filed an 8-K on May 14, 2025, reporting on financial statements and exhibits, and a Regulation FD Disclosure. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.

Why It Matters

This filing provides updates on Aptose Biosciences' financial and regulatory disclosures, which are important for investors to understand the company's current status and compliance.

Risk Assessment

Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 14, 2025.

What is Aptose Biosciences Inc.'s Standard Industrial Classification code?

Aptose Biosciences Inc.'s Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).

What were some of Aptose Biosciences Inc.'s former company names?

Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.

In which jurisdiction is Aptose Biosciences Inc. incorporated?

Aptose Biosciences Inc. is incorporated in Canada.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding Aptose Biosciences Inc. (APTOF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing